What Happened?
Cambridge, MA-based Spero Therapeutics Appointed Ankit Mahadevia as Chief Executive Officer
About the Company
Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.
About the Person
Ankit Mahadevia serves as Founder and Chief Executive Officer at Spero Therapeutics in Greater Boston Area. Investor and entrepreneur at Atlas Venture, an early stage life sciences and technology venture capital firm. I'm focused on forming new companies and making investments in novel platforms and therapies.
Info Source
Press Release
Short Profile